ARDELYX, INC. Long-Term Debt, Maturity, Year Two
ARDELYX, INC. (ARDX) had Long-Term Debt, Maturity, Year Two of $0 as of 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Two and Three
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo · last filed 2024-02-22
- 2023-12-31: Long-Term Debt, Maturity, Year Two $0.00.
- 2022-12-31: Long-Term Debt, Maturity, Year Two $7.64M.
- 2020-12-31: Long-Term Debt, Maturity, Year Two $48.31M.
- 2020-06-30: Long-Term Debt, Maturity, Year Two $25.00M.
| Period end | Long-Term Debt, Maturity, Year Two |
|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 |
| 2022-12-31 | $7.64M 10-K · filed 2023-03-02 |
| 2020-12-31 | $48.31M 10-K · filed 2021-03-08 |
| 2020-06-30 | $25.00M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $25.00M 10-Q · filed 2020-05-07 |
| 2019-12-31 | $25.00M 10-K · filed 2020-03-06 |
| 2019-09-30 | $2.08M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $2.08M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $2.08M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $2.08M 10-K · filed 2019-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |